Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and Ibrutinib for Chronic Graft-Versus-Host Disease
NCT04235036Phase 2Terminated
- Sponsor
- Northside Hospital
- Start
- Dec 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ibrutinib and rituximab in chronic graft-versus-host disease (cGVHD), sponsored by Northside Hospital. Primary endpoint: Number of Patients Who Remain Off Immunosuppressive Therapy at 12 months. Started Dec 2019; status: terminated.
02
Drugs
ibrutinibrituximab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT04235036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04235036.